Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
29/05/2024 13:04
May 29 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES ANNOUNCES NEW TUMOR RESPONSE DATA FROM
ONGOING
RANDOMIZED CONTROLLED PHASE 2B STUDY OF VBI-1901 IN RECURRENT
GLIOBLASTOMA PATIENTS
* VBI VACCINES INC: EXPECT TO HAVE ADDITIONAL TUMOR
RESPONSE DATA
AND INITIAL SURVIVAL DATA THROUGHOUT REMAINDER OF 2024
Source text for Eikon: ID:nBw4YQtSWa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55